Pipeline

We are working to deliver best-in-class pan-variant TKIs to fight cancer.

Our pipeline focuses on developing next-generation TKIs that address the key limitation of drug resistance.
Program/Target
Indication Stage
Discovery
IND-Enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
GIST IND-Enabling
NSCLC Discovery
3rd Kinase Target Undisclosed
Undisclosed Discovery